FHIR Server FHIR Server Version n/a

Resource CodeSystem/FHIR Server from package hl7.terminology.r4b#6.0.2 (78 ms)

Package

hl7.terminology.r4b

Type

CodeSystem

FHIR Version

R4B

Source

http://terminology.hl7.org/http://terminology.hl7.org/6.0.2/CodeSystem-v3-nciThesaurus.html

Url

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl

Version

3.0.0

Status

active

Date

2022-10-13T00:00:00-04:00

Name

NciThesaurus

Title

NCI Thesaurus

Experimental

False

Realm

Authority

hl7

Description

NCI Thesaurus NCI Thesaurus is a biomedical thesaurus created specifically to meet the needs of the cancer research community, especially those engaged in translational research NCI Thesaurus is produced by the NCI Enterprise Vocabulary Services project. The NCI Thesaurus is provided under an open content license.

Content

not-present

Resources that use this resource

CodeSystem

http://hl7.org/fhir/us/pq-cmc-fda/CodeSystem/cmc-hierarchy-supplement

PQ-CMC-FDA NCIt Hieararchy Supplement

http://hl7.org/fhir/us/icsr-ae-reporting/ValueSet/PatientMilitaryStatus

Patient Military Status

http://hl7.org/fhir/us/mcode/ValueSet/mcode-all-risk-assessment-value-vs

Acute Lymphoblastic Leukemia (ALL) Risk Assessment Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-binet-stage-value-vs

Binet Stage Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-cancer-stage-type-vs

Cancer Stage Type Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-cancer-stage-value-vs

Cancer Stage Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-cancer-staging-method-vs

Cancer Staging Method Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-deauville-scale-vs

Deauville Scale Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-figo-stage-value-vs

FIGO Stage Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-international-retinoblastoma-stage-value-vs

International Retinoblastoma Stage Value

http://hl7.org/fhir/us/mcode/ValueSet/mcode-lansky-play-performance-vs

Lansky Play Performance Status VS

http://hl7.org/fhir/us/mcode/ValueSet/mcode-lymphoma-stage-value-vs

Lymphoma Stage Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-lymphoma-staging-method-vs

Lymphoma Staging System Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-myeloma-iss-stage-value-vs

International Staging System (ISS) for Myeloma Stage Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-myeloma-riss-stage-value-vs

Revised International Staging System (ISS) for Multiple Myeloma Stage Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-neuroblastoma-INRGSS-value-vs

International Neuroblastoma Risk Group Staging System (INRGSS) for Neuroblastoma Risk Assessment Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-pretext-stage-value-vs

PRETEXT Stage Value

http://hl7.org/fhir/us/mcode/ValueSet/mcode-rai-stage-value-vs

Rai Stage Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-rai-staging-method-vs

Rai Staging System Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-rhabdomyosarcoma-assessment-value-vs

Rhabdomyosarcoma Assessment Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-rhabdomyosarcoma-clinical-group-value-vs

Rhabdomyosarcoma Clinical Group Value

http://hl7.org/fhir/us/mcode/ValueSet/mcode-risk-assessment-type-vs

Risk Assessment Type Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-risk-assessment-vs

Risk Assessment Value Set

http://hl7.org/fhir/us/mcode/ValueSet/mcode-tnm-staging-method-vs

TNM Staging Method Value Set

http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-causality-relatedness

Adverse Event Clinical Research Causality Relatedness

http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-grades

Adverse Event Clinical Research Grades

http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-outcomes

Adverse Event Clinical Research Outcomes

http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-seriousness-criteria

Adverse Event Clinical Research Seriousness Criteria

http://hl7.org/fhir/uv/emedicinal-product-info/ValueSet/propertyColor

Color of the product

http://hl7.org/fhir/uv/emedicinal-product-info/ValueSet/propertyFlavor

Flavor of the product

http://hl7.org/fhir/uv/emedicinal-product-info/ValueSet/propertyShape

Shape of the product

http://hl7.org/fhir/uv/phenomics-exchange/ValueSet/DiagnosticMarker

Diagnostic Marker

http://hl7.org/fhir/uv/phenomics-exchange/ValueSet/HistologicalDiagnosis

HistologicalDiagnosis

http://hl7.org/fhir/uv/phenomics-exchange/ValueSet/TumorGrade

Tumor Grade

http://hl7.org/fhir/uv/phenomics-exchange/ValueSet/TumorProgression

Tumor Progression

http://hl7.org/fhir/uv/phenomics-exchange/ValueSet/TumorStage

Tumor Stage

http://hl7.org/fhir/uv/phenomics-exchange/ValueSet/phenotypic-abnormality

Phenotypic abnormality ValueSet

http://hl7.org/fhir/us/codex-radiation-therapy/ValueSet/codexrt-radiotherapy-adverse-event-termVS

Adverse Event Terms Value Set

http://hl7.org/fhir/us/spl/ValueSet/valueset-businessOperationQualifiers

Business Operation Qualifiers

http://hl7.org/fhir/us/spl/ValueSet/valueset-establishmentBusinessOperations

Establishment Business Operations

http://hl7.org/fhir/us/spl/ValueSet/valueset-gdufaFacilityBusinessOperationQualifiers

GDUFA Facility Business Operation Qualifiers

http://hl7.org/fhir/us/spl/ValueSet/valueset-gdufaFacilityBusinessOperations

GDUFA Facility Business Operations

http://hl7.org/fhir/us/spl/ValueSet/valueset-labelerBusinessOperations

Labeler Business Operations

http://hl7.org/fhir/us/spl/ValueSet/valueset-splColor

SPL Color

http://hl7.org/fhir/us/spl/ValueSet/valueset-splComboProductType

SPL Combo Product Type

http://hl7.org/fhir/us/spl/ValueSet/valueset-splDoseForm

SPL Dose Form

http://hl7.org/fhir/us/spl/ValueSet/valueset-splFlavor

SPL Flavor

http://hl7.org/fhir/us/spl/ValueSet/valueset-splMarketingCategories

SPL Marketing Categories

http://hl7.org/fhir/us/spl/ValueSet/valueset-splOperationType

SPL Operation Type

http://hl7.org/fhir/us/spl/ValueSet/valueset-splPackageTypes

SPL Package Types

http://hl7.org/fhir/us/spl/ValueSet/valueset-splRouteOfAdministration

SPL Route of Administration

http://hl7.org/fhir/us/spl/ValueSet/valueset-splShape

SPL Shape

http://hl7.org/fhir/us/spl/ValueSet/valueset-splSpecialMeasures

SPL Special Measures

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/capsule-classification-category

Capsule Shell Classification Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/cmc-product-name-types-vs

Product Name Types Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-batch-utilization-terminology

Batch utilization Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-chemical-structure-datafile-type-terminology

Chemical Structure Data File Type Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-closure-type-terminology

Closure Type Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-coating-purpose

Coating Purpose Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-container-type-terminology

Container Type Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-drug-product-component-function-category-terminology

Drug Product Component Function Category Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-excipient-function-terminology

Excipient Function Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-impurity-classification-terminology

Impurity Classification Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-manufactured-dose-form-terminology

Manufactured Dose Form Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-org-identifier-type-terminology

Organization-Site Identifier Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-product-part-ingredient-physical-location

Ingredient Location Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-product-part-type

Product Part Type Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-quality-benchmark-terminology

Quality Benchmark Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-release-mechanism

Release Mechanism Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-release-profile

Release Profile Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-representation-types

Representation Types

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-source-type-terminology

Source Type Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-specification-status-terminology

Specification Status Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-specification-type-terminology

Specification Type Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-strength-type-terminology

Strength Type Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-substance-name-type

Substance Name Type

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-test-category-terminology

Test Category Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-test-method-origin-terminology

Test Method Origin Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/pqcmc-test-usage-terminology

Test Usage Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/spl-drug-route-of-administration-terminology

Drug Route Of Administration Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/spl-pharmaceutical-dosage-form-terminology

Pharmaceutical Dosage Form Terminology

http://hl7.org/fhir/us/pq-cmc-fda/ValueSet/substance-classification

Substance Classification

http://hl7.org/fhir/uv/genomics-reporting/ValueSet/molecular-biomarker-code-vs

Molecular Biomarker Codes

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-cd-datacollected-nci

NFDI4Health Data Collected [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-cd-information-sources-nci-local

NFDI4Health Data Collected [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-id-type-nci-local

NFDI4Health VS MDS ID Type [NCI, local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-identifier-type-related-artifact-nci-local

NFDI4Health VS MDS Identifier Type Related Artifact [NCI, local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-mortality-data-nci

NFDI4Health VS MDS Mortality Data [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-ne-instrument-nci-local

NFDI4Health NE Instrument [NCI, Local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-ne-mode-nci-msh-local

NFDI4Health NE Mode [NCI, MeSH, Local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-organisational-roles-nci-local

NFDI4Health VS MDS Organisational Roles [NCI, local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-personal-roles-nci-local

NFDI4Health VS MDS Personal Roles [NCI, local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-population-coverage-nci

NFDI4Health VS MDS Population Coverage [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-resource-type-general-nci-msh-local

NFDI4Health VS MDS Resource Type General [NCI, MSH, local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-resource-type-nci-local

NFDI4Health VS MDS Resource Type [NCI, Local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-allocation-nci

NFDI4Health VS MDS Study Allocation [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-arm-group-type-nci

NFDI4Health VS MDS Study Arm Group Type [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-assessments-sct-nci

NFDI4Health VS MDS Study Assessments [SCT, NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-biospecimen-retention-nci

NFDI4Health VS MDS Study Biospecimen Retention [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-conditions-classification-nci-local

NFDI4Health VS MDS Study Conditions Classification [NCI, Local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-data-sharing-plan-ds-sct-nci

NFDI4Health VS MDS Study Data Sharing Plan Datashield [SCT, NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-data-sharing-plan-sup-inf-nci-local

NFDI4Health VS MDS Study Data Sharing Plan Supporting Information [NCI, local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-data-sources-general-nci-local

NFDI4Health VS MDS Study Data Sources General [NCI, local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-data-sources-imaging-nci

NFDI4Health VS MDS Study Data Sources Imaging [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-data-sources-omics-nci

NFDI4Health VS MDS Study Data Sources Omics [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-ds-biosamples-sct-nci

NFDI4Health VS MDS Study Data Sources Biosamples [SCT, NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-ethics-committee-approval-nci-local

NFDI4Health VS MDS Study Ethics Commitee Approval [NCI, local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-exposure-type-nci

NFDI4Health VS MDS Study Exposure Type [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-group-characteristics-nci

NFDI4Health VS MDS Study Group Characteristics [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-intervention-type-nci

NFDI4Health VS MDS Study Intervention Type [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-masking-roles-nci-local

NFDI4Health VS MDS Study Masking Roles [NCI, local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-outcome-type-nci

NFDI4Health VS MDS Study Outcome Type [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-overall-status-nci-local

NFDI4Health VS MDS Study Overall Status [NCI, Local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-phase-nci

NFDI4Health VS MDS Study Phase [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-primary-design-nci

NFDI4Health VS MDS Study Primary Design [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-primary-purpose-hl7-nci

NFDI4Health VS MDS Study Primary Purpose [HL7, NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-recruitment-register-nci-sct-local

NFDI4Health VS MDS Study Recruitment Register [NCI, SCT, Local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-sampling-method-nci-local

NFDI4Health VS MDS Study Sampling Method [NCI, local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-sampling-method-non-prob-nci-local

NFDI4Health VS MDS Study Sampling Method Non Probability [NCI, local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-sampling-prob-method-nci-local

NFDI4Health VS MDS Study Sampling Probability Method [NCI, Local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-time-perspectives-nci

NFDI4Health VS MDS Study Time Perspectives [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-type-interventional-nci

NFDI4Health VS MDS Study Type Interventional [NCI]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-study-type-non-interventional-nci-msh-local

NFDI4Health VS MDS Study Type Non Interventional [NCI, MSH, local]

https://www.nfdi4health.de/fhir/metadataschema/ValueSet/nfdi4health-vs-mds-yes-no-undecided-snomedct-nci

NFDI4Health VS MDS Yes, No, Undecided [SNOMED CT, NCI]

http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-causality-relatedness

Adverse Event Clinical Research Causality Relatedness

http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-grades

Adverse Event Clinical Research Grades

http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-outcomes

Adverse Event Clinical Research Outcomes

http://terminology.hl7.org/ValueSet/adverse-event-clinical-research-seriousness-criteria

Adverse Event Clinical Research Seriousness Criteria

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.30

AdministrationUnitDoseForm

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.46

Device Magnetic resonance (MR) Safety

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.47

Device Latex Safety

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.48

Implantable Device Status

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.292

Non pharmacologic treatments for chronic pain NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.36

Non pharmacologic treatments for chronic pain

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.100

MMR Proficient

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.11

Estrogen Receptor Test for Orserdu

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.116

Localized Bladder Cancer Staging

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.119

Localized Bladder Cancer T Stage

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.128

FGFR3 Gene

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.13

HER2 Negative

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.131

FGFR3 Gene Interpretation Positive NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.133

FGFR3 Gene Interpretation Positive

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.135

FGFR3 Gene Interpretation Negative NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.137

FGFR3 Gene Interpretation Negative

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.138

FGFR3 Molecular Variants

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.190

Localized NSCLC Stage Group NCIM

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.192

Localized NSCLC Stage Group

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.198

EGFR Gene

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.203

EGFR Generic Molecular Variant NCIM

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.206

EGFR Molecular Variants Osimertinib PM

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.214

Radiation Treatment Delivery NCIM

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.216

Radiation Treatment Delivery

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.227

MET Exon 14 skipping molecular variant

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.235

ROS1 Repotrectinib Molecular Variants

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.237

ROS1 Negative (geneinterpretation) NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.238

ROS1 Negative (geneinterpretation) SNOMEDCT,NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.240

ROS1 results (HGNC)

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.246

RET Negative (geneinterpretaion) NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.247

RET Negative (geneinterpretaion) SNOMEDCT,NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.248

RET Fusion Molecular Variants

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.25

ESR1 Gene Test

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.26

ESR1 Genetic Mutation

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.260

ALK Positive (geneinterpretation) NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.261

ALK Positive (geneinterpretation) SNOMEDCT NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.263

ALK Negative (geneinterpretation) NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.264

ALK Negative (geneinterpretation) SNOMEDCT NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.277

Extensive SCLC Stage Group NCIM

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.278

Extensive SCLC Stage Group

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.28

Her2 Negative

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.30

HER2 Positive

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.305

HER2 Negative (geneinterpretation/Labtestvalue) NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.307

HER2 Negative (geneinterpretation/Labtestvalue)

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.311

Localized_Solid_Cancer_Stage Group NCIM

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.313

Localized_Solid_Cancer_Stage Group

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.314

Locally_Advanced_Solid_Cancer_Stage Group NCIM

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.315

Locally_Advanced_Solid_Cancer_Stage Group

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.316

Metastatic_Solid_Cancer_Stage Group NCIM

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.317

Metastatic_Solid_Cancer_Stage Group

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.319

Solid Cancer T Stage NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.32

HER2 Positive

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.320

Solid Cancer T Stage codes

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.325

RET fusion Molecular Variants_Solid_Cancer

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.344

PTEN_gene

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.346

PIK3CA_gene

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.348

AKTI_gene

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.350

Progesterone_receptor_gene

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.352

Estrogen_receptor_gene

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.359

HER2_IHC_test_Gene

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.372

HER2 test_gene

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.416

KRAS_G12C_MV

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.429

Localized_Endometerial_Stage Group NCIM

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.460

Localized_Endometerial_Stage Group_SNOMED/NCIM

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.465

NTRK Repotrectinib Molecular Variants

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.55

MSI High

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.57

Early Stage IIB or lower

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.60

MMR Deficient

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.61

Stage IIB or lower and limited

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.63

Stage III or higher

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.64

Stage III or higher

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.66

Staging Unknown

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.67

Staging Unknown

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.84

RAS Gene Interpretation Negative NCM

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.85

RAS Gene Negative

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.9

ER Test for Orserdu

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.91

MSI High NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.94

MSI Low NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.95

MSI Low

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.96

MMR Deficient NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.99

MMR Proficient NCI

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.22

Route of Administration of Therapeutic Agents

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.11

Medication Product Form

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.7

SPL Drug Route of Administration Terminology

http://uk-koeln.de/fhir/ValueSet/nNGM/anforderung-liquidBiopsy

ValueSet - nNGM - Anforderung Liquid Biopsy

http://uk-koeln.de/fhir/ValueSet/nNGM/anforderung-molekularpathologie

ValueSet - nNGM - Anforderung Molekularpathologie

http://uk-koeln.de/fhir/ValueSet/nNGM/MaterialTyp

ValueSet - nNGM - MaterialTyp

http://uk-koeln.de/fhir/ValueSet/nNGM/tki-resistenz

ValueSet - nNGM - TKI Resistenz

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: CodeSystem v3-nciThesaurus

This case-sensitive code system http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl defines codes, but no codes are represented here

Source

{
  "resourceType" : "CodeSystem",
  "id" : "v3-nciThesaurus",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem v3-nciThesaurus</b></p><a name=\"v3-nciThesaurus\"> </a><a name=\"hcv3-nciThesaurus\"> </a><a name=\"v3-nciThesaurus-en-US\"> </a><p>This case-sensitive code system <code>http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl</code> defines codes, but no codes are represented here</p></div>"
  },
  "url" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.26.1.1"
    }
  ],
  "version" : "3.0.0",
  "name" : "NciThesaurus",
  "title" : "NCI Thesaurus",
  "status" : "active",
  "experimental" : false,
  "date" : "2022-10-13T00:00:00-04:00",
  "publisher" : "TBD - External Body",
  "contact" : [
    {
      "name" : "National Cancer Institute"
    }
  ],
  "description" : "NCI Thesaurus NCI Thesaurus is a biomedical thesaurus created specifically to meet the needs of the cancer research community, especially those engaged in translational research NCI Thesaurus is produced by the NCI Enterprise Vocabulary Services project. The NCI Thesaurus is provided under an open content license.",
  "caseSensitive" : true,
  "content" : "not-present"
}

XIG built as of ??metadata-date??. Found ??metadata-resources?? resources in ??metadata-packages?? packages.